142 related articles for article (PubMed ID: 19965558)
1. Disease progression among multiple sclerosis patients before and during a disease-modifying drug program: a longitudinal population-based evaluation.
Veugelers PJ; Fisk JD; Brown MG; Stadnyk K; Sketris IS; Murray TJ; Bhan V
Mult Scler; 2009 Nov; 15(11):1286-94. PubMed ID: 19965558
[TBL] [Abstract][Full Text] [Related]
2. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
[TBL] [Abstract][Full Text] [Related]
3. Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis.
Healy BC; Engler D; Gholipour T; Weiner H; Bakshi R; Chitnis T
J Neurol Sci; 2011 Apr; 303(1-2):109-13. PubMed ID: 21251671
[TBL] [Abstract][Full Text] [Related]
4. Disability as an outcome in MS clinical trials.
Ebers GC; Heigenhauser L; Daumer M; Lederer C; Noseworthy JH
Neurology; 2008 Aug; 71(9):624-31. PubMed ID: 18480462
[TBL] [Abstract][Full Text] [Related]
5. Factors associated with the risk of secondary progression in multiple sclerosis.
Koch M; Uyttenboogaart M; van Harten A; De Keyser J
Mult Scler; 2008 Jul; 14(6):799-803. PubMed ID: 18573840
[TBL] [Abstract][Full Text] [Related]
6. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
7. [Immunomodulatory therapy in multiple sclerosis].
Csépány T; Bereczki D
Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
[TBL] [Abstract][Full Text] [Related]
8. Is late-onset multiple sclerosis associated with a worse outcome?
Tremlett H; Devonshire V
Neurology; 2006 Sep; 67(6):954-9. PubMed ID: 17000960
[TBL] [Abstract][Full Text] [Related]
9. Progression in familial and nonfamilial MS.
Koch M; Uyttenboogaart M; Heerings M; Heersema D; Mostert J; De Keyser J
Mult Scler; 2008 Apr; 14(3):300-6. PubMed ID: 18208881
[TBL] [Abstract][Full Text] [Related]
10. Assessing disability progression with the Multiple Sclerosis Functional Composite.
Rudick RA; Polman CH; Cohen JA; Walton MK; Miller AE; Confavreux C; Lublin FD; Hutchinson M; O'Connor PW; Schwid SR; Balcer LJ; Lynn F; Panzara MA; Sandrock AW
Mult Scler; 2009 Aug; 15(8):984-97. PubMed ID: 19667023
[TBL] [Abstract][Full Text] [Related]
11. Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.
Trojano M; Pellegrini F; Paolicelli D; Fuiani A; Zimatore GB; Tortorella C; Simone IL; Patti F; Ghezzi A; Portaccio E; Rossi P; Pozzilli C; Salemi G; Lugaresi A; Bergamaschi R; Millefiorini E; Clerico M; Lus G; Vianello M; Avolio C; Cavalla P; Iaffaldano P; Direnzo V; D'Onghia M; Lepore V; Livrea P; Comi G; Amato MP;
J Neurol Sci; 2009 Nov; 286(1-2):109-13. PubMed ID: 19615696
[TBL] [Abstract][Full Text] [Related]
12. Benign multiple sclerosis in Crete.
Mastorodemos V; Nikolakaki H; Tzagournissakis M; Kotzamani D; Panou T; Spanaki C; Klados G; Maris T; Kontolaimaki E; Psaroudaki K; Chlouverakis G; Georgakakis G; Plaitakis A
Mult Scler; 2010 Jun; 16(6):701-6. PubMed ID: 20237192
[TBL] [Abstract][Full Text] [Related]
13. Natural history of secondary-progressive multiple sclerosis.
Tremlett H; Yinshan Zhao ; Devonshire V
Mult Scler; 2008 Apr; 14(3):314-24. PubMed ID: 18208898
[TBL] [Abstract][Full Text] [Related]
14. Disability progression in multiple sclerosis is slower than previously reported.
Tremlett H; Paty D; Devonshire V
Neurology; 2006 Jan; 66(2):172-7. PubMed ID: 16434648
[TBL] [Abstract][Full Text] [Related]
15. Natural history of multiple sclerosis: a unifying concept.
Confavreux C; Vukusic S
Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
[TBL] [Abstract][Full Text] [Related]
16. Age at onset determines the occurrence of the progressive phase of multiple sclerosis.
Stankoff B; Mrejen S; Tourbah A; Fontaine B; Lyon-Caen O; Lubetzki C; Rosenheim M
Neurology; 2007 Mar; 68(10):779-81. PubMed ID: 17339588
[TBL] [Abstract][Full Text] [Related]
17. Predictors of relapse rate in MS clinical trials.
Held U; Heigenhauser L; Shang C; Kappos L; Polman C;
Neurology; 2005 Dec; 65(11):1769-73. PubMed ID: 16344520
[TBL] [Abstract][Full Text] [Related]
18. Cigarette smoking and progression in multiple sclerosis.
Koch M; van Harten A; Uyttenboogaart M; De Keyser J
Neurology; 2007 Oct; 69(15):1515-20. PubMed ID: 17923613
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the natural history and prognostic features of early onset and adult onset multiple sclerosis in Jordanian population.
El-Salem K; Khader Y
Clin Neurol Neurosurg; 2007 Jan; 109(1):32-7. PubMed ID: 16870328
[TBL] [Abstract][Full Text] [Related]
20. Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis.
Parry A; Corkill R; Blamire AM; Palace J; Narayanan S; Arnold D; Styles P; Matthews PM
J Neurol; 2003 Feb; 250(2):171-8. PubMed ID: 12574947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
